SAR-439459 is under clinical development by Sanofi and currently in Phase I for Osteogenesis Imperfecta. According to GlobalData, Phase I drugs for Osteogenesis Imperfecta have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SAR-439459’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAR-439459 is under development for the treatment of osteogenesis imperfecta. The drug candidate is formulated as a powder for solution and is administered through intravenous route. The drug candidate targets TGF-beta. The drug candidate is a new molecular entity. It was under development for the treatment of relapsed or refractory multiple myeloma, solid tumors including colorectal adenocarcinoma, metastatic melanoma, hepatocellular carcinoma (HCC), non-small cell lung cancer and urothelial cancer.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of SAR-439459’s drug-specific PTSR and LoA scores, buy the report here.